

# BC Cancer Protocol Summary for DOXOrubicin for Use in Patients with Advanced Endometrial Cancer

**Protocol Code**

GOENDD

**Tumour Group**

Gynecologic Oncology

**Contact Physician**

Dr. Anna Tinker

## ELIGIBILITY:

- Patients with an advanced epithelial endometrial cancer, MMMT, or carcinosarcoma
- Good performance status

## EXCLUSIONS:

- Poor bone marrow reserve, renal dysfunction, hepatic dysfunction (bilirubin greater than 2xULN)

## TESTS:

- Baseline and before each treatment: CBC & diff, platelets, creatinine, bilirubin, ALT, alk phos, GGT, LDH and clinical measure of tumor response
- Every second treatment: appropriate imaging to monitor response

## PREMEDICATIONS:

- Antiemetic protocol for High/Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

## TREATMENT:

Drug	Dose	BC Cancer Administration Guidelines
DOXOrubicin	75 mg/m <sup>2</sup>	IV push

- For patients greater than 65 years old, consider reducing dose to 60 mg/m<sup>2</sup>
- Repeat every 21 days x 6 cycles

## DOSE MODIFICATIONS:

### 1. Hematological:

ANC (x 10 <sup>9</sup> /L)		Platelets (x 10 <sup>9</sup> /L)	Dose
greater than 1.5	and	greater than 100	100 %
1 to 1.5	or	70 to 100	80 %
less than 1	or	less than 70	Delay one week

- Mucositis:** Grade 3 or 4, reduce dose to 80%
- Nausea & Vomiting:** Grade 4 despite optimal use of antiemetics, reduce dose to 80% or QUIT
- Neutropenic Fever** (with ANC less than 0.5 x 10<sup>9</sup>/L): Once counts have recovered, reduce dose to 80%
- Hepatic Dysfunction:** For bilirubin 1.5 to 2 times ULN, reduce dose to 50%

## PRECAUTIONS:

- Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution in patients with severe hypertension or cardiac dysfunction. Cardiac assessment is recommended if lifelong dose of 450 mg/m<sup>2</sup> is exceeded (see BCCA Cancer Drug Manual).
- Extravasation:** DOXOrubicin causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.
- Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

**Call Dr. Anna Tinker or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**